Grants for Nonprofits - Federal

This funding opportunity supports collaborative research projects aimed at addressing brain and nervous system disorders in low- and middle-income countries, focusing on building sustainable research capacity and improving neuro-health outcomes.

The "Office of Postsecondary Education (OPE): Fund for The Improvement of Postsecondary Education (IFPSE): Transitioning Gang-Involved Youth to Higher Education Program" grant aims to financially support organizations that assist gang-involved youth in pursuing higher education for obtaining certification or credentials.

With this solicitation, BJS seeks to provide funding for the Technical Assistance Program to support activities under the State Justice Statistics Program for Statistical Analysis Centers (SJS-SAC) in FY 2024. The SJS-SAC is designed to maintain and enhance each states capacity to coordinate statistical activities in the state, conduct research on relevant criminal justice issues, and serve as a liaison to help BJS gather data from state agencies.

This notice is subject to availability of funding. A. PROGRAM DESCRIPTION U.S. Embassy Belgrade of the U.S. Department of State announces an open competition for organizations to submit applications for the Democracy Commission Small Grants Program. Please follow all instructions below. Priority Region: Serbia Program Objectives: Proposals should align with the U.S. Embassys objectives to strengthen democracy and protect human rights and empower local organizations to advance these changes and reforms throughout Serbia. Grant activities may take any number of forms, including trainings, conferences, workshops, courses, academic competitions, summer camps (focused on language study, sports, etc.), cross-border exchanges, curriculum development, exhibits, hackathons, or app development, online projects, mock trials or moot court competitions, simulations, and role-playing activities (e.g., Model Congress, Model United Nations), film or theater festivals, performances, or other activities. The proposal should also demonstrate how the program will further engagement in underserved communities and with individuals from underserved communities. Proposals should demonstrate how addressing racial equity and underserved communities will enhance the programs goals and objectives, as well as the experience of participants. Participants and Audiences: Primary audiences for proposals should be youth, students, teachers and administrators, young professionals, and/or others related to your program theme. Depending on focus, projects may have secondary audiences or beneficiaries including media, civil society organizations or wider professional audiences, which you may note in the proposal. Participants or audiences for the proposal should be citizens or legal residents of Serbia. If your project idea might involve citizens of other countries, please see the full text of the NOFO, to understand restrictions on funding. B. FEDERAL AWARD INFORMATION Length of performance period: Any length of time up to a maximum of 18 months (including the 3-month evaluation period). Number of awards anticipated: Approximately 10 awards (dependent on amounts) Award amounts: awards may range from a minimum of $10,000 to a maximum of $50,000 Total available funding: $265,000 Type of Funding: FY23/24 Economic Support Funds under the Foreign Assistance Act. Anticipated program start date: Your project should start no earlier than July 1, 2024, and no later than September 30, 2025. Note: PDS strongly recommends that first-time applicants keep their budget under $25,000. Cost Sharing or Matching: Cost sharing is allowed but not required and will not impact funding decisions. While filling out the application, you will be required to tell us whether you are also receiving funding from other donors for your project. Please be aware, however, that you must be able to carry out all the activities described in your application with the funding you receive, even if the contributions from other donors or other funding sources fail to materialize. C. APPLICATION AND SUBMISSION INFORMATION 1. Requesting the Application Package: Application forms required below are available at https://rs.usembassy.gov/grants-programs 2. Content and Form of Application Submission: Please follow all instructions below carefully. Proposals that do not meet the requirements of this announcement or fail to comply with the stated requirements will be ineligible. Content of Application Please ensure: The proposal clearly addresses the goals and objectives of this funding opportunity All documents are in English All budgets are in U.S. dollars All pages are numbered All documents are formatted to 8 x 11 paper, and All Microsoft Word documents are single-spaced, 12 point Calibri font, with a minimum of 1-inch margins. The following documents are required: 1. Mandatory application forms SF-424 (Application for Federal Assistance organizations) SF-424A (Budget Information for Non-Construction programs) SF-424B (Assurances for Non-Construction programs) (note: the SF-424B is only required for individuals and for organizations not registered in SAM.gov) 2. Grant Application Form for FY2024 (Fiscal year 2024). Note: Detailed instructions for filling out the grant application are included with the form. 3. Budget Justification Narrative (Excel Spreadsheet): After filling out the SF-424A Budget (above), use the Excel spreadsheet template to describe and explain each of the budget expenses in detail. See section Other Information: Guidelines for Budget Submissions in the full text of the NOFO for further information. 4. Attachments: 1-page CV or resume of all key personnel who are proposed for the program Letters of support from program partners describing the roles and responsibilities of each partner, if applicable. If your organization has a Negotiated Indirect Cost Rate Agreement (NICRA) and includes NICRA charges in the budget, your latest NICRA should be included as a PDF file. Official permission letters, if required for program activities. If you still have not completed SAM.gov registration, a screenshot from SAM.gov reflecting that you have started the process. APR (Agencija za privredne registre) document to prove that your organization is a non-profit organization. Required Registrations: All organizations, whether based in the United States or in another country, must have a Unique Entity Identifier (UEI) and an active registration with the SAM.gov. A UEI is one of the data elements mandated by Public Law 109-282, the Federal Funding Accountability and Transparency Act (FFATA), for all Federal awards. To be eligible for consideration, every Serbia-based applicant organization must also be registered in the territory of the Republic of Serbia with the Agencija za privredne registre (APR), or the relevant court. Submission Dates and Times; Applications are due no later than May 10, 2024 at 15:00h. Funding Restrictions: You may NOT apply for a grant from PDS if your project: involves partisan political activity. funds attendance at overseas conferences or trips abroad. international travel to/from the U.S. or countries outside the Balkan region. involves giving charitable activity and humanitarian aid. involves fundraising. is commercial in nature, i.e., you are making money. focuses on academic or scientific research. is focused on arts, culture, or any other areas beyond the themes listed above. is focused on skill learning or training programs unless the activity is specifically aimed at promoting the integration of disadvantaged groups into society. duplicates an already existing project. involves the provision of health care or services, childcare, food subsidies, or other social services to populations. This funding opportunity aims to support specific projects with objectives which can be achieved within a set timeframe. We will not accept applications which are aimed more broadly at supporting your organizations usual or typical daily activities and operations. Those will be deemed technically ineligible and will not be considered for funding by the review committee. Other Submission Requirements: All application materials must be submitted by email to [email protected]. If PDS does not receive a complete project proposal at the above address by the deadline, it will be considered technically ineligible and will not be considered for funding. MAXIMUM LENGTH IS 10 (TEN) PAGES (NOT INCLUDING ATTACHMENTS). As a backup, we strongly recommend that you also send a paper copy via post (postmarked before the deadline) to the following address: Democracy Commission Public Diplomacy Section (PDS), U.S. Embassy Bulevar Kneza Aleksandra Karadjordjevica 92 11040 Belgrade Review and Selection Process: A review committee will evaluate all eligible applications. You may be asked to submit additional information and/or a revised budget. Please also be aware that, depending on the availability of funding, PDS might be able to fund only part of the budget that you have requested. Anticipated Announcement and Federal Award Dates: PDS anticipates that final funding decisions will be made by July 1, 2024. D. FEDERAL AWARDING AGENCY CONTACTS If you have any questions about the grant application process, please contact: [email protected] The full text of the NOFO and the required documents are available at https://rs.usembassy.gov/grants-programs/ and in the Related Documents tab.

demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the best and brightest in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the demonstrated ability of the individual named as the Principal Investigator (PI) in the application to go beyond conventional thinking in their field and the innovative contribution that the PI can make toward ending breast cancer. The application should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award. Individuals from other disciplines who apply novel concepts to breast cancer are encouraged to submit.The PI is encouraged to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. The PIs research team must include two or more breast cancer consumer advocates. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they may not be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 Era of Hope Scholar Award should not exceed $3.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $5.4M to fund approximately one Era of Hope Scholar Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.

Every year more than 795,000 people in the United States have a stroke. On average, thats 1 person every 40 seconds. On average, 1 American dies from a stroke every 3 minutes and 14 seconds. Approximately 9.4 million American adults 20 years of age self-report having had a stroke. These data are disturbing, more so as 80% of strokes are preventable.Prevention begins with implementing equity-focused systems and interventions that assist populations at the highest risk in detecting and managing cardiovascular disease (CVD) and mitigating systemic social conditions that contribute to the increased prevalence of CVD. Roughly 1 in 10 (9.9% 28.6 million) adults in the US have at least 1 type of CVD, including coronary heart disease, heart failure, or stroke. This number excludes hypertension, a risk factor for and cause of CVD but not a type of CVD. However, hypertension or high blood pressure is a critical risk factor for stroke. An estimated 120 million American adults (48.1%) have it, most (3 in 4) dont have it controlled, and 1 in 5 adults is unaware they have hypertension. High blood cholesterol, smoking, obesity, and diabetes also contribute to stroke risk.Heart disease, stroke, and their modifiable risk factors are experienced disproportionately throughout the US population based on race and ethnicity, social factors, and geography. Non-Hispanic Black Americans have a higher prevalence and highest death rate from stroke than any other racial group. While non-Hispanic Blacks had the highest age-adjusted stroke death among all races and ethnicities (59.6 per 100,000) in 2021, the age-adjusted stroke death rate for individuals across the board increased from 38.8 per 100,000 in 2020 to 41.1 per 100,000 in 2021. Stroke deaths also increased in southern states, where populations at a higher risk, specifically communities of color, exist. These numbers highlight the critical need to improve access to quality care for those at the highest risk of stroke and for stroke patients.In 2001, Congress provided funding to CDC to establish the Paul Coverdell National Acute Stroke Registry, named after the late US Senator Paul Coverdell of Georgia, who suffered a fatal stroke in 2000 while serving in Congress. In 2012, as the program expanded, the name changed to the Paul Coverdell National Acute Stroke Program. The aim has been to support the implementation of comprehensive stroke systems for individuals at the highest risk of stroke and for stroke patients across the continuum of care from the onset of stroke symptoms through rehabilitation and recovery.This new iteration of Coverdell supports state stroke systems in partnerships with learning collaboratives or coalitions to improve state-level stroke care for those at the highest risk. Recipients will be required to execute a dual approach to addressing stroke in the coordinated systems of care and the implementation of prevention activities in community settings. Recipients will continue their collection and analysis of in-hospital stroke data for those who have experienced a stroke while adding a deep focus on understanding and mitigating the stroke risks among individuals in their communities, also ensuring post-discharge follow-up in either rehabilitation facilities or other community-supportive recovery services.This NOFO requires Coverdell recipients to integrate their work with CDCs other funded programs in states where they exist to mitigate systemic inequities and reduce the prevalence of CVD and hypertension so that another person doesnt die from a stroke every 3 minutes and 14 seconds.

This funding opportunity provides $4 million to organizations that can strengthen public health systems and enhance health security in Mali, particularly in challenging and insecure areas.

This funding opportunity provides financial support for non-profit organizations to create educational and job-training programs for young adults interested in careers in natural resources management, focusing on hands-on conservation work and environmental stewardship.

This funding opportunity supports collaborative research teams in developing sustainable polymers through advanced data analytics and artificial intelligence, aiming to foster innovation and train a skilled workforce in this field.

The purpose of the Cooperative Agreement is to restore a total of 450 linear feet in two separate reaches with measures to provide structural repair and erosion prevention strategies along the indicated stream at Naval Support Facility Indian Head (NSFIH), located in northwestern Charles County, Maryland. The work shall include all necessary measures to meet the stream restoration efforts to reduce erosion and Nonpoint Source (NPS) pollution. These measures will include installing stream erosion control measures through living shoreline, bolder toe, gabion removal, native plantings, and supporting measures to reduce shoreline erosion. This project will already have all the necessary designs and permitting in place. The Cooperator shall abide by the permits issued by Charles County, the State of Maryland, the US Army Corps of Engineers, and any others.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

This funding opportunity supports Tribal Nations and collaboratives in enhancing their involvement and capacity in offshore wind energy projects, including site assessments and environmental compliance, while integrating Traditional Ecological Knowledge.

This funding opportunity provides financial support to various government and nonprofit organizations for developing and implementing emergency preparedness plans in juvenile justice residential facilities to ensure the safety and well-being of youth and staff during emergencies.

This funding opportunity provides financial support for projects that develop and demonstrate innovative carbon capture technologies at existing industrial and power facilities, aiming to reduce greenhouse gas emissions and promote clean energy solutions.

This funding opportunity provides financial support to organizations that improve mental health services for children, youth, and families, focusing on collaboration, training, and engagement in the systems of care approach.

This grant provides funding to establish a comprehensive online resource for research and policy information to support child care and early education programs, helping agencies improve access to valuable research for children from birth to age 13.

This grant provides funding to public health organizations and healthcare providers in the United States to improve prevention, diagnosis, and management of parasitic infections, particularly focusing on Chagas disease, soil-transmitted helminths, and other significant domestic parasitic diseases.

This program provides funding to support tree planting and urban forestry projects in disadvantaged communities across Georgia, promoting long-term environmental benefits.

It is the policy of my Administration to advance womens health research, close health disparities, and ensure that the gains we make in research laboratories are translated into real-world clinical benefits for women. It is also the policy of my Administration to ensure that women have access to high-quality, evidence-based health care and to improve health outcomes for women across their lifespans and throughout the country. President Joseph R. Biden, Jr., Executive Order 14120 on Advancing Womens Health Research and Innovation, 18 March 2024.In support of the Presidents Executive Order to advance womens health research, the PRORP is releasing this WHRA funding opportunity. The intent of the FY24 PRORP WHRA is to support research focused on orthopaedic issues faced by women serving in military settings, such as infantry and other physically demanding roles, who have sustained orthopaedic injuries. The overall goal of the WHRA is to address factors that contribute to the health and retention of women in military service. Although use of military populations, datasets, or samples are not required, the application should demonstrate how the proposed research relates to issues faced by women serving in military settings. The proposed research project should also include a well-formulated, testable hypothesis based on sound scientific rationale and logical reasoning.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.The PRORP encourages applications from a spectrum of research areas, including but not limited to translational and clinical research. The PRORP also welcomes qualitative research, population science, and health care services research specifically designed to understand the impact of orthopaedic injuries on female Service Members.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the PRORP WHRAs focus on orthopaedic injuries in women.A key feature of the PRORP WHRA is the relevance to female military and/or Veteran populations following orthopaedic injury. Inclusion of female military and/or Veteran populations is highly encouraged for applications proposing clinical research. Applicants proposing clinical studies in non-military and/or non-Veteran populations must justify the relevance of the proposed research to the military and/or Veteran communities. All applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.Research involving human subjects, human datasets, and human anatomical substances is permitted; however, the WHRA may not be used to conduct clinical trials. Applicants seeking support for a clinical trial should consider the FY24 PRORP Clinical Trial Award (Funding Opportunity Number HT942524PRORPCTA).Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 7, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.Encouraged Department of Defense (DOD) and/or VA Collaboration: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP WHRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.0M to fund approximately two WHRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.